C2CD4A Inhibitors
C2CD4A inhibitors are a class of chemical compounds that specifically target the C2CD4A protein, which is a member of the C2 domain-containing protein family. This family is known for proteins that contain C2 domains, enabling calcium-dependent interactions with phospholipids and other membrane components. C2CD4A plays a role in cellular signaling pathways, particularly those involving membrane-associated processes such as vesicle trafficking, intracellular communication, and membrane organization. By binding to the C2 domain or other critical regions of the C2CD4A protein, these inhibitors block its normal function, which disrupts its ability to mediate interactions between cellular membranes and signaling molecules. C2CD4A inhibitors thus provide researchers with a tool to explore the protein's specific role in maintaining cellular structure and communication.
The design of C2CD4A inhibitors requires an understanding of the protein's structure, particularly its C2 domain and any other functional regions necessary for its role in cellular processes. These inhibitors are often small molecules or peptides engineered for high specificity to ensure that only C2CD4A is affected, while minimizing interference with other C2 domain-containing proteins. By selectively inhibiting C2CD4A, these compounds allow researchers to investigate its function in various cellular mechanisms, such as its involvement in calcium-dependent signaling and membrane dynamics. The ability to modulate the activity of C2CD4A through inhibition is essential for studying how this protein influences complex intracellular networks and how it contributes to overall cellular organization and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits C2CD4A by disrupting the PI3K/Akt pathway, specifically targeting the phosphorylation of Akt at Ser473. This interference impedes the downstream signaling cascades involved in C2CD4A activation, leading to reduced protein function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Acting as a selective mTOR inhibitor, Rapamycin hinders the mTORC1 complex, thereby modulating the downstream pathways linked to C2CD4A. By disrupting mTOR-dependent signaling, this chemical indirectly curtails the activation of C2CD4A and its associated cellular responses. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits C2CD4A through its impact on the NF-κB signaling pathway. By suppressing the phosphorylation and degradation of IκBα, this chemical interferes with the activation of NF-κB, subsequently influencing the downstream processes involving C2CD4A. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A JAK2 inhibitor, Ruxolitinib disrupts the JAK/STAT pathway, which is intricately connected to C2CD4A regulation. Through its selective inhibition of JAK2, this compound modulates the signaling cascades that converge on C2CD4A, resulting in attenuated protein activation. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
A Wnt pathway inhibitor, LGK-974 attenuates C2CD4A activation indirectly by disrupting Wnt-mediated signaling. By interfering with the canonical Wnt pathway, this chemical modulates the downstream events that converge on C2CD4A, resulting in diminished protein activity. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine inhibits C2CD4A by disrupting the Hedgehog signaling pathway. Through its impact on the Gli transcription factors, this chemical interferes with the downstream events associated with C2CD4A, leading to attenuated protein activation and altered cellular responses. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
An AMPK activator, AICAR indirectly inhibits C2CD4A by influencing cellular energy metabolism. By activating AMPK, this chemical modulates the metabolic pathways connected to C2CD4A, resulting in altered protein activation and downstream cellular responses. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a selective HDAC inhibitor, influences the epigenetic regulation of genes associated with C2CD4A. Through its impact on histone acetylation, this chemical modulates the transcriptional control of C2CD4A, leading to altered protein expression and function. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
INK128, an mTORC2 inhibitor, disrupts the mTOR signaling pathway, indirectly affecting C2CD4A. By selectively inhibiting mTORC2, this chemical modulates the downstream events connected to C2CD4A, resulting in altered protein activation and cellular responses. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT inhibits C2CD4A by influencing the Notch signaling pathway. Through its impact on Notch receptors, this chemical interferes with the downstream events associated with C2CD4A, leading to attenuated protein activation and altered cellular responses. | ||||||